RxDoctor Payments DataLook up a doctor →

Pedro Hernandez, MD

Nephrology · Pembroke Pines, FLNPI 1649498569

Payments from drug & device makers

$910,378in general payments, 2019–2025

Across 187 payments — averaging $4868.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$357K
  • AstraZeneca$181K
  • Amgen$144K
  • Eli Lilly$90K
  • Merck$77K
  • CSL Behring$57K
  • plus $3K from 20 others

What the payments were for

  • Travel & lodging$45713%
  • Food & beverage$2,69078%
  • Education$3049%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$910,378 in reported general payments places this provider in the 95th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$432,377
Medicare patients
526
Services billed
2,802

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JynarqueTolvaptan13$256,608
JardianceEmpagliflozin81$85,848
FarxigaDapagliflozin Propanediol45$47,974
Sevelamer Carbonate107$21,887
OzempicSemaglutide15$14,600
Lanthanum Carbonate13$10,610
LokelmaSodium Zirconium Cyclosilicate16$8,606
Cinacalcet Hcl16$5,431
Nifedipine ErNifedipine145$5,283
Torsemide231$4,806
Calcium Acetate95$4,346
Sodium Polystyrene Sulfonate41$3,465
SpsSodium Polystyrene Sulfon/Sorb13$2,539
Mycophenolate Mofetil14$2,075
Megestrol Acetate11$1,987

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Jynarque$771$256,60813 claims
Boehringer IngelheimJardiance$45$85,84881 claims
AstraZenecaFarxiga, Lokelma$181,487$56,58061 claims
Novo NordiskOzempic$81$14,60015 claims
ANI Pharmaceuticals, Inc.Valsartan$34$1,11639 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 756 nephrology providers in Florida.

Other nephrology in Pembroke Pines

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →